NClip

Immunosuppressants

2 min read

Immunosuppressants

Key Points

  • Immunosuppressants reduce immune activity to prevent organ rejection or control autoimmune disease.
  • Increased infection risk is the primary and most dangerous adverse effect.
  • Classes include calcineurin inhibitors (cyclosporine, tacrolimus), antimetabolites (azathioprine, mycophenolate), and mTOR inhibitors.
  • Glucocorticoids can provide short-term immunosuppressive control but require careful tapering after prolonged use.
  • Azathioprine and mycophenolate require structured CBC, liver, and renal monitoring due to marrow and organ toxicity risk.
  • Mycophenolate has major teratogenic risk and is generally avoided in pregnancy unless specialist-directed risk-benefit decisions are made.
  • Skipped doses can precipitate autoimmune flare or graft-rejection events, so adherence counseling is a safety priority.

Mechanism

Immunosuppressants interrupt specific immune pathways. Calcineurin inhibitors block T-cell activation signals. Antimetabolites (for example azathioprine, mycophenolate) inhibit DNA synthesis in proliferating lymphocytes. Glucocorticoids suppress broad inflammatory cascades and are often used short term or as bridge therapy because long-term toxicity burden is high.

Key Nursing Considerations

  • Monitor for infection signs (fever, neutropenia, unusual pathogens) and hold/escalate promptly for active serious infection.
  • Teach urgent escalation cues in transplant or high-risk immunosuppression contexts: fever >=100.5 F (38 C), reduced urine output, hematuria, flu-like symptoms, or new rash/lesion drainage.
  • Check drug levels (especially cyclosporine, tacrolimus) to prevent nephrotoxicity.
  • For azathioprine/mycophenolate pathways, trend CBC, liver enzymes, serum creatinine, and ordered lipid monitoring during long-term therapy.
  • Monitor for expected adverse-effect clusters and escalate significant progression: hyperglycemia, fatigue, tremor, headache, hypertension, GI intolerance, weight change, osteoporosis risk, and hair-loss complaints.
  • Screen and document vaccine history before starting therapy; avoid live vaccines while actively immunosuppressed.
  • Teach patients to minimize exposure to infectious contacts and report persistent cough, fever, mucosal ulcers, bleeding, or unusual bruising.
  • Review interaction alerts, including azathioprine with xanthine-oxidase inhibitors (for example allopurinol/febuxostat), and ensure dose-adjustment plans are verified.

Graph View